Literature DB >> 27063269

Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver Disease.

Vaishali Patel1, Arun J Sanyal1, Richard Sterling2.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a diagnosis of exclusion. Most patients are asymptomatic and diagnosed incidentally. Most patients remain undiagnosed. A high index of suspicion and serologic work-up to rule out alternative causes of liver disease is required. In NALFD, fibrosis correlates with outcomes, including mortality. To diagnose, assess severity, and monitor fibrosis, 2 noninvasive methods can be used. However, noninvasive tests are more helpful at extremes of fibrosis: excluding it or diagnosing advanced fibrosis. Liver biopsy is usually reserved for cases whereby noninvasive tests fail to accurately determine the degree of fibrosis or the diagnosis is unclear.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Evaluation; Nonalcoholic fatty liver; Steatohepatitis

Mesh:

Year:  2016        PMID: 27063269     DOI: 10.1016/j.cld.2015.10.006

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  11 in total

Review 1.  Drug-induced steatohepatitis.

Authors:  Ajit Dash; Robert A Figler; Arun J Sanyal; Brian R Wamhoff
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-10-27       Impact factor: 4.481

2.  Primary Versus Secondary NAFLD: Perspective on Advanced Fibrosis.

Authors:  Divya Shetty; Anjali Amarapurkar; Akash Shukla
Journal:  J Clin Exp Hepatol       Date:  2020-12-31

3.  β-Hydroxybutyrate is reduced in humans with obesity-related NAFLD and displays a dose-dependent effect on skeletal muscle mitochondrial respiration in vitro.

Authors:  Jacob T Mey; Melissa L Erickson; Christopher L Axelrod; William T King; Chris A Flask; Arthur J McCullough; John P Kirwan
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-05-12       Impact factor: 4.310

4.  A microfluidic patterned model of non-alcoholic fatty liver disease: applications to disease progression and zonation.

Authors:  Beyza Bulutoglu; Camilo Rey-Bedón; Young Bok Abraham Kang; Safak Mert; Martin L Yarmush; O Berk Usta
Journal:  Lab Chip       Date:  2019-09-10       Impact factor: 6.799

5.  Safety and Effectiveness of Essential Phospholipids Paste in Patients with Non-alcoholic Fatty Liver Disease or Viral Hepatitis.

Authors:  Vladimir T Ivashkin; Igor V Maev; Chavdar S Pavlov; Marina V Mayevskaya; Aleksey A Samsonov; Lyudmila K Palgova; Kirill M Starostin
Journal:  Turk J Gastroenterol       Date:  2021-09       Impact factor: 1.555

Review 6.  Non-alcoholic fatty liver disease: An expanded review.

Authors:  Mark Benedict; Xuchen Zhang
Journal:  World J Hepatol       Date:  2017-06-08

7.  A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains.

Authors:  G Craig Wood; Xin Chu; George Argyropoulos; Peter Benotti; David Rolston; Tooraj Mirshahi; Anthony Petrick; John Gabrielson; David J Carey; Johanna K DiStefano; Christopher D Still; Glenn S Gerhard
Journal:  Sci Rep       Date:  2017-03-07       Impact factor: 4.379

Review 8.  Relationship Between Ginsenoside Rg3 and Metabolic Syndrome.

Authors:  Hyunji Lee; Gyeyeong Kong; Quangdon Tran; Chaeyeong Kim; Jisoo Park; Jongsun Park
Journal:  Front Pharmacol       Date:  2020-02-25       Impact factor: 5.810

Review 9.  Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease.

Authors:  Alejandro Campos-Murguía; Astrid Ruiz-Margáin; José A González-Regueiro; Ricardo U Macías-Rodríguez
Journal:  World J Gastroenterol       Date:  2020-10-21       Impact factor: 5.742

Review 10.  Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.

Authors:  Maria Grazia Clemente; Claudia Mandato; Marco Poeta; Pietro Vajro
Journal:  World J Gastroenterol       Date:  2016-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.